Counting the carbon cost of heparin: an evolving tragedy of the commons?

Bingwen Eugene Fan, Emmanuel J Favaloro

Research output: Contribution to journalComment/debatepeer-review

7 Citations (Scopus)


Heparin, which is listed in WHO's Model List of Essential Medicines, 1 was discovered in 1916 and has been used as an anticoagulant since 1935, possessing potentiating effects on antithrombin. The global demand for heparin is rising, with the global heparin pharmaceutical market projected to grow from US$9·38 billion in 2021 to US$12·06 billion in 2028, and there is a possibility that demand might outstrip supply. 2 In addition to increased usage for treatment of rising cardiovascular disease and thrombosis cases in ageing populations, the demand for heparin has been exacerbated by its use during the COVID-19 pandemic for thromboprophylaxis and treatment of COVID-19-associated thromboembolic disease.
Original languageEnglish
Pages (from-to)e469-e471
JournalThe Lancet Haematology
Issue number7
Early online date07 Jun 2022
Publication statusPublished - Jul 2022


Dive into the research topics of 'Counting the carbon cost of heparin: an evolving tragedy of the commons?'. Together they form a unique fingerprint.

Cite this